6.48BMarket Cap
23.57P/E TTM
Key Figures
101.030Open
101.030High
1.02MVolume
23.57P/E TTM
15.04P/E Dynamic
--Dividend TTM
1.57%Turnover Ratio
101.000Prev. Close
98.810Low
80.02MTurnover
20.75P/E Static
5.35P/B
0.00%Div Yield TTM
12.68%ROA
103.89052wk High
0.74Volume Ratio
312.44MNet Profit
65.07MShares
4.2278EPS TTM
-0.04Beta
23.48%ROE
47.25052wk Low
2.20%Amplitude
61.20%Gross Margin
6.48BMarket Cap
-0.75Reward/Risk
2.37%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Lantheus Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 107.15.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lantheus Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Lantheus Holdings Inc Highlights
StrengthsRisks
Lantheus Holdings Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Lantheus Holdings Inc
LNTH
13
Zimmer Biomet Holdings Inc
ZBH
31
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lantheus Holdings Inc Info
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Ticker SymbolLNTH
CompanyLantheus Holdings Inc
CEOMarkison (Brian A)
Websitehttps://www.lantheus.com/
Shareholders
FAQs
What is the current price of Lantheus Holdings Inc (LNTH)?
The current price of Lantheus Holdings Inc (LNTH) is 99.67.
What is the symbol of Lantheus Holdings Inc?
The ticker symbol of Lantheus Holdings Inc is LNTH.
What is the 52-week high of Lantheus Holdings Inc?
The 52-week high of Lantheus Holdings Inc is 103.89.
What is the 52-week low of Lantheus Holdings Inc?
The 52-week low of Lantheus Holdings Inc is 47.25.
What is the market capitalization of Lantheus Holdings Inc?
The market capitalization of Lantheus Holdings Inc is 6.49B.
Is Lantheus Holdings Inc (LNTH) currently rated as Buy, Hold, or Sell?
According to analysts, Lantheus Holdings Inc (LNTH) has an overall rating of Buy, with a price target of 107.15.
What is the Earnings Per Share (EPS TTM) of Lantheus Holdings Inc (LNTH)?
The Earnings Per Share (EPS TTM) of Lantheus Holdings Inc (LNTH) is 3.46.
